Clinical Trials Day is celebrated around the world on May 20 to commemorate James Lind who started what is often considered the first randomized clinical trial aboard a ship on May 20, 1747. Pharma organizations, clinical research professionals and the industry overall acknowledge the achievements that result from clinical trials. One of the biggest obstacles still facing clinical trials is having enough patients volunteer so that the trials can begin and funding sources.

New Communications

Social media continues to expand as communication method to reach patients who could potentially participate in a clinical trial.  Out-Sourcing Pharma.com recently wrote “With an estimated 320 million active users, Twitter could potentially serve as new, unexploited resource to stimulate interest and enrollment in clinical trials”. The entire process of how patients communicate has become easier and more widespread with not just Twitter but other social platforms such as Facebook and some sites specifically devoted to patient symptoms, resources, and outcomes. Patients can access information on clinical trials, how others benefit from a trial benefit and provide or research answers to questions posed by other clinical trial patients. The clinical research industry is becoming more involved by actively engaging in these discussions with the patients and by including links to enrollment sites.

New Funding

Crowd funding has been used for everything from bio-printers to human rights. Now crowd funding is becoming a forum to spread the word by people who have a particular disease themselves or a family member with the disease or even enthusiasts for a cure. Reliance on grants and crowd funding philanthropy can now be combined with other finances while also providing an online connection between participating patients and donors.

New Ideas and Innovation from Marken 

Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. Marken maintains the leading position for Direct to Patient services and biological sample shipments, and offers a state of the art GMP-compliant depot network and logistic hubs in 43 locations worldwide. Marken’s 630 staff members manage 50,000 drug and biological shipments every month at all temperature ranges in more than 150 countries.  Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry. 

The market is growing and Marken is growing with it. The rapid increase in the use of biologic drug and temperature-sensitive products, cell & gene therapies and direct to patient logistic demands from clients are providing us a unique opportunity to qualify new service providers, enforce our stringent GDP requirements on our network, provide new services, and continually expand our state-of-the-art technology. Our focus will always be on the patient and their needs, and to bring the treatments and therapies as close and convenient to the patient as possible.